C-reactive protein is associated with the severity of cognitive impairment but not of psychiatric symptoms in individuals with schizophrenia

C-REACTIVE PROTEIN IS ASSOCIATED WITH THE SEVERITY OF COGNITIVE IMPAIRMENT BUT NOT OF PSYCHIATRIC SYMPTOMS IN INDIVIDUALS WITH SCHIZOPHRENIA

Schizophr Res. 2007 Jul;94(1-3):261-5. Epub 2007 May 8

Dickerson F, Stallings C, Origoni A, Boronow J, Yolken R

Stanley Research Center at Sheppard Pratt, Sheppard Pratt Health System, 6501 North Charles St., Baltimore, MD 21204 USA

ABSTRACT

OBJECTIVES: We investigated the association between serum levels of C-reactive protein (CRP), a marker of inflammation, and the severity of psychopathology and cognitive impairment in schizophrenia. METHODS: We measured the levels of CRP in N=413 individuals with schizophrenia. Symptom severity was evaluated with the Positive and Negative Syndrome Scale (PANSS) and cognitive functioning with the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS). RESULTS: The individuals with CFP >/=5.0 mg/mul had significantly lower RBANS cognitive scores than those with CRP <5.0 mg/mul (F=8.07, p<.005). However the CRP groups did not differ in the severity of positive, negative, or general PANSS symptoms (all P>.2). CONCLUSIONS: Elevated serum levels of C-reactive protein in schizophrenia are associated with the severity of cognitive impairment but not of psychiatric symptoms. The long term consequences of elevated levels of CRP require further investigation.